var data={"title":"Filgrastim (including biosimilars of filgrastim): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Filgrastim (including biosimilars of filgrastim): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6197?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-drug-information\" class=\"drug drug_general\">see &quot;Filgrastim (including biosimilars of filgrastim): Drug information&quot;</a> and <a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-patient-drug-information\" class=\"drug drug_patient\">see &quot;Filgrastim (including biosimilars of filgrastim): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171203\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Granix;</li>\n      <li>Neupogen;</li>\n      <li>Zarxio</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171204\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Grastofil;</li>\n      <li>Neupogen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047358\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Colony-Stimulating Factor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hematopoietic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11442533\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> International considerations: Dosages below expressed as micrograms; 1 mcg = 100,000 units (H&ouml;glund 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenia with sepsis:</b> IV, SubQ: 10 mcg/kg/day divided every 12 to 24 hours for 3 to 14 days; most trials have used once daily dosing for 3 days (Carr 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenia, prophylaxis of infection:</b> IV, SubQ: 5 to 10 mcg/kg/day for 3 to 5 days (Carr 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neutropenia, congenital:</b> SubQ: Initial: 5 mcg/kg/day, followed by 10 mcg/kg/day; then titrate to response using 10 mcg/kg/day increments every 14 days until target ANC (1,000 to 1,500/mm<sup>3</sup>) is reached and maintained; if ANC exceeds 5,000/mm<sup>3</sup>, dosage should be reduced to lowest effective dose. Typical dose range for response of patients included in the international CN registry is 3 to 10 mcg/kg/day; maximum dose: 120 mcg/kg/day (Boztug 2008; Welte 2006)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047351\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-drug-information\" class=\"drug drug_general\">see &quot;Filgrastim (including biosimilars of filgrastim): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Do not administer in the period 24 hours before to 24 hours after cytotoxic chemotherapy. International considerations: Dosages below expressed as micrograms; 1 mcg = 100,000 units (H&ouml;glund 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Details concerning dosing in combination regimens and institution protocols should also be consulted. For larger doses (eg, adolescents), rounding doses to the nearest vial size may enhance patient convenience and reduce costs without compromising clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone marrow transplantation, slow engraftment:</b> Infants, Children, and Adolescents: Limited data available: IV, SubQ: 5 mcg/kg/day administered &ge;24 hours after cytotoxic chemotherapy and &ge;24 hours after bone marrow infusion (Schaison 1998; Wagner 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced neutropenia:</b> Neupogen, Zarxio: Infants, Children, and Adolescents: IV, SubQ: 5 mcg/kg/day once daily beginning &ge;24 hours after chemotherapy; recommendations for duration of therapy vary: Manufacturer labeling is for up to 14 days or until ANC reaches 10,000/mm<sup>3</sup>; others have suggested a lower target ANC of 5,000/mm<sup>3</sup> (Schaison 1998; Wagner 2001). For subsequent chemotherapy cycles, dose may be increased by 5 mcg/kg based upon patient&rsquo;s previous response to therapy along with duration and severity of neutropenia; reported range: 4 to 8 mcg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic syndrome of acute radiation syndrome, acute: </b>Neupogen: Infants, Children, and Adolescents: SubQ: 10 mcg/kg/day once daily; begin as soon as possible after suspected or confirmed radiation doses &gt;2 gray (Gy) and continue filgrastim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs or ANC exceeds 10,000/mm<sup>3</sup> after the radiation-induced nadir. ASCO guidelines recommend initiating within 24 hours of exposure of a dose &ge;2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for &ge;7 days (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neutropenia, severe, chronic:</b> Neupogen, Zarxio: Infants, Children, and Adolescents: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Congenital:</i> Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; median dose: 6 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Idiopathic:</i> Initial: 5 mcg/kg/day in 1 or 2 divided doses; adjust the dose based on ANC and clinical response; median dose: 1.2 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cyclic</i>: Initial: 5 mcg/kg/day in 1 or 2 divided doses; adjust the dose based on ANC and clinical response; median dose: 2.1 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neutropenia due to zidovudine for HIV treatment:</b> Limited data available: Infants, Children, and Adolescents: SubQ: 5 to 10 mcg/kg/day once daily; doses as high as 20 mcg/kg/day once daily have been used (Mueller 1992; Working Group 2008). <b>Note:</b> Trials performed with Neupogen product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peripheral blood progenitor cell (PBPC) mobilization, autologous bone marrow transplant (Neupogen, Zarxio):</b> Infants, Children, and Adolescents: Limited data available: IV, SubQ: 10 mcg/kg/day given for 4 to 5 days before apheresis procedure (Diaz 2000; Wagner 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: Details concerning dosing in combination regimens and institution protocols should also be consulted. Rounding doses to the nearest vial size may enhance patient convenience and reduce costs without compromising clinical response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute myeloid leukemia (AML) following induction or consolidation chemotherapy: </b>Neupogen, Zarxio<b>:</b> SubQ, IV: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the ANC reaches 10,000/mm<sup>3</sup>. Discontinue if the ANC surpasses 10,000/mm<sup>3</sup> after the expected chemotherapy-induced neutrophil nadir.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone marrow transplantation (in patients with cancer; to shorten the duration of neutropenia and neutropenia-related events):</b> Neupogen, Zarxio: IV infusion: 10 mcg/kg/day (administer &ge;24 hours after chemotherapy and &ge;24 hours after bone marrow infusion); adjust the dose according to the duration and severity of neutropenia; recommended steps based on neutrophil response:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">When ANC &gt;1,000/mm<sup>3</sup> for 3 consecutive days: Reduce filgrastim dose to 5 mcg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If ANC remains &gt;1,000/mm<sup>3</sup> for 3 more consecutive days: Discontinue filgrastim.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If ANC decreases to &lt;1,000/mm<sup>3</sup>: Resume at 5 mcg/kg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If ANC decreases to &lt;1,000/mm<sup>3</sup> during the 5 mcg/kg/day dose: Increase filgrastim to 10 mcg/kg/day and follow the above steps</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematopoietic radiation injury syndrome, acute: </b>Neupogen<b>:</b> SubQ: 10 mcg/kg once daily; begin as soon as possible after suspected or confirmed radiation doses &gt;2 gray (Gy) and continue filgrastim until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs or ANC exceeds 10,000/mm<sup>3</sup> after the radiation-induced nadir. ASCO guidelines recommend initiating within 24 hours of exposure of a dose &ge;2 Gy and/or significant decrease in absolute lymphocyte count, or for anticipated neutropenia &lt;500/mm<sup>3</sup> for &ge;7 days (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Myelosuppressive chemotherapy recipients with nonmyeloid malignancies: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Neupogen, Zarxio<b>:</b> SubQ, IV: 5 mcg/kg/day; doses may be increased by 5 mcg/kg (for each chemotherapy cycle) according to the duration and severity of the neutropenia; continue for up to 14 days until the absolute neutrophil count (ANC) reaches 10,000/mm<sup>3</sup>. Discontinue if the ANC surpasses 10,000/mm<sup>3</sup> after the expected chemotherapy-induced neutrophil nadir.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Granix: SubQ: 5 mcg/kg/day; continue until anticipated nadir has passed and neutrophil count has recovered to normal range</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peripheral blood progenitor cell (PBPC) collection and therapy:</b> Neupogen, Zarxio: SubQ: 10 mcg/kg/dose once daily, usually for 6 to 7 days (with apheresis occurring on days 5, 6, and 7). Begin at least 4 days before the first apheresis and continue until the last apheresis; discontinue for WBC &gt;100,000/m<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Severe chronic neutropenia:</b> Neupogen, Zarxio: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Congenital</i>: Initial: 6 mcg/kg/day in 2 divided doses; adjust the dose based on ANC and clinical response; mean dose: 6 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Idiopathic:</i> Initial: 5 mcg/kg once daily; adjust the dose based on ANC and clinical response; total daily dose may be administered in 1 or 2 divided doses; mean dose: 1.2 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Cyclic</i>: Initial: 5 mcg/kg/day; adjust the dose based on ANC and clinical response; total daily dose may be administered in 1 or 2 divided doses; mean dose: 2.1 mcg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neupogen, Zarxio: All patients: No dosage adjustment necessary; if patient develops glomerulonephritis due to filgrastim, consider dose reduction or interruption of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granix: Adults: If patient develops glomerulonephritis due to filgrastim, consider dose reduction or interruption of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Mild impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Moderate to severe impairment: There are no dosage adjustments provided in the manufacturer&prime;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neupogen, Zarxio: All patients: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granix: Adults: There are no dosage adjustments provided in the manufacturer&prime;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171179\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupogen: filgrastim 300 mcg/mL (1 mL); filgrastim 480 mcg/1.6 mL (1.6 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupogen: filgrastim 300 mcg/0.5 mL (0.5 mL); filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zarxio: filgrastim-sndz 300 mcg/0.5 mL (0.5 mL); filgrastim-sndz 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Granix: tbo-filgrastim 300 mcg/0.5 mL (0.5 mL); tbo-filgrastim 480 mcg/0.8 mL (0.8 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171164\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22627092\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-drug-information\" class=\"drug drug_general\">see &quot;Filgrastim (including biosimilars of filgrastim): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Filgrastim-sndz (Zarxio) is approved as a biosimilar to filgrastim (Neupogen).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047363\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Administer into the outer upper arm, abdomen, front middle thigh, or the upper outer buttocks area. Rotate injection site; do not inject into areas that are tender, red, bruised, hardened, or scarred, or sites with stretch marks. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Neupogen, Zarxio: May be administered IV as a short infusion over 15 to 30 minutes (chemotherapy-induced neutropenia) or by continuous infusion (chemotherapy-induced neutropenia) or as an infusion of no longer than 24 hours (bone marrow transplantation). Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171199\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neupogen: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Store in the original carton. Protect from light. Protect from direct sunlight. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard if frozen more than once. Do not shake. Transport via a pneumatic tube has not been studied. Prior to injection, allow to reach room temperature for up to 30 minutes and a maximum of 24 hours. Discard any vial or prefilled syringe left at room temperature for more than 24 hours. Solutions diluted for infusion in D5W may be stored at room temperature for up to 24 hours (infusion must be completed within 24 hours of preparation).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended storage information may be available for undiluted filgrastim; contact product manufacturer to obtain current recommendations. Sterility has been assessed and maintained for up to 7 days when prepared under strict aseptic conditions (Jacobson 1996; Singh 1994). The manufacturer recommends using within 24 hours due to the potential for bacterial contamination.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granix: Store prefilled syringes at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Do not shake. May be removed from 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) storage for a single period of up to 5 days between 23&deg;C to 27&deg;C (73&deg;F to 81&deg;F). If not used within 5 days, the product may be returned to 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) up to the expiration date. Dispose of syringes if stored at room temperature for more than 5 days. Exposure to -1&deg;C to -5&deg;C (23&deg;F to 30&deg;F) for up to 72 hours and temperatures as low as -15&deg;C to -25&deg;C (5&deg;F to -13&deg;F) for up to 24 hours do not adversely affect stability. Discard unused product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zarxio: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Store in the original carton. Protect from light. Avoid freezing; if frozen, thaw in the refrigerator before administration. Discard if frozen more than once. Do not shake. Transport via a pneumatic tube has not been studied. Prior to injection, allow to reach room temperature for up to 30 minutes and a maximum of 24 hours. Discard any prefilled syringe left at room temperature for more than 24 hours. Solutions diluted for infusion may be stored at room temperature for up to 24 hours (infusion must be completed within 24 hours of preparation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grastofil [Canadian product]: Store at 2&ordm;C to 8&ordm;C (36&deg;F to 46&deg;F). Protect from light. Do not shake. Accidental one-time exposure to temperatures up to 30&ordm;C (86&deg;F) or exposure to freezing temperatures &lt;0&ordm;C (32&deg;F) does not adversely affect stability. If exposure at &gt;30&ordm;C or &lt;0&ordm;C has been greater than 24 hours or frozen more than once, do not use. May be removed from the refrigerator and stored at room temperature (&le;25&deg;C) for a single period of up to 7 days. Do not return to refrigerator.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047362\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cancer patients (nonmyeloid malignancies) receiving myelosuppressive chemotherapy:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuprogen, Zarxio: Decrease the incidence of infection in patients receiving regimens associated with a high occurrence of severe neutropenia with fever (FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Granix (tbo-filgrastim): Reduce the duration of severe neutropenia in patients receiving regimens associated with a clinically significant incidence of febrile neutropenia (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myelogenous leukemia (AML):</b> Reduce time to neutrophil recovery and duration of fever, following induction or consolidation chemotherapy (Neupogen, Zarxio: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cancer patients (nonmyeloid malignancies) receiving bone marrow transplant</b>: Reduce the duration of neutropenia and neutropenia-related events (eg, febrile neutropenia) undergoing myeloablative chemotherapy followed by bone marrow transplantation [Neupogen, Zarxio: FDA approved in adults]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic syndrome of acute radiation syndrome:</b> Improve survival in patients acutely exposed to myelosuppressive doses of radiation [Neupogen: FDA approved in pediatric patients (age not specified) and adults]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Peripheral stem cell transplantation:</b> Mobilization autologous hematopoietic progenitor cells into peripheral blood for apheresis collection [Neupogen, Zarxio: FDA approved in adults]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Severe chronic neutropenia (SCN; chronic administration):</b> Reduce the incidence and duration of neutropenic complications (fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital, cyclic, or idiopathic neutropenia (Neupogen, Zarxio: FDA approved in ages &ge;1 month and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Has also been used for HIV patients receiving zidovudine; neonatal neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note: </b>Zarxio (Filgrastim-sndz) is a biosimilar agent; approved uses and ages may vary, see product labeling for additional information</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171257\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Filgrastim may be confused with filgrastim-sndz, tbo-filgrastim</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Neupogen may be confused with Epogen, Neulasta, Neumega, Nutramigen</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neupogen [US, Canada, and multiple international markets] may be confused with Neupro brand name for rotigotine [multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Some products available internationally may have vial strength and dosing expressed as units (instead of as micrograms). Refer to prescribing information for specific strength and dosing information.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171253\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrhythmia, chest pain, hypertension, myocardial infarction, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, fatigue, headache, hypoesthesia, insomnia, malaise, mouth pain, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, erythema, maculopapular rash, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-4em;margin-left:4em;margin-right:2em;\">Gastrointestinal: Constipation, decreased appetite, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukocytosis, petechia, splenomegaly (more common in severe chronic neutropenia), thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction, transfusion reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (no evidence of neutralizing response)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, muscle spasm, musculoskeletal pain, ostealgia (dose and cycle related), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchitis, cough, dyspnea, epistaxis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (dose and cycle related)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, capillary leak syndrome, cerebral hemorrhage, decreased bone mineral density, decreased hemoglobin, euthymia nodosum, exacerbation of psoriasis, facial edema, glomerulonephritis, hematuria, hemoptysis, hepatomegaly, hypersensitivity angiitis, hypotension, injection site reaction, osteoporosis, proteinuria, pulmonary alveolar hemorrhage, pulmonary infiltrates, renal insufficiency, respiratory distress syndrome, severe sickle cell crisis, splenic rupture, Sweet syndrome, tachycardia, urticaria, wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171186\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">History of serious allergic reactions to human granulocyte colony-stimulating factors, such as filgrastim or pegfilgrastim, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Neupogen, Grastofil: Known hypersensitivity to <i>E. coli-</i>derived products</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171168\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse reactions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Serious allergic reactions (including anaphylaxis) have been reported, usually with the initial exposure; may be managed symptomatically with administration of antihistamines, steroids, bronchodilators, and/or epinephrine. Allergic reactions may recur within days after the initial allergy management has been stopped. Do not administer filgrastim products to patients who have experienced serious allergic reaction to filgrastim or pegfilgrastim. Permanently discontinue filgrastim products in patients with serious allergic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alveolar hemorrhage: Reports of alveolar hemorrhage, manifested as pulmonary infiltrates and hemoptysis (requiring hospitalization), have occurred in healthy donors undergoing PBPC mobilization (off-label for use in healthy donors); hemoptysis resolved upon discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Capillary leak syndrome: Capillary leak syndrome (CLS), characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration, may occur in patients receiving human granulocyte colony-stimulating factors (G-CSF). CLS episodes may vary in frequency and severity. If CLS develops, monitor closely and manage symptomatically (may require intensive care). CLS may be life-threatening if treatment is delayed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous vasculitis: Moderate or severe cutaneous vasculitis has been reported, generally occurring in patients with severe chronic neutropenia on chronic therapy. Withhold treatment if cutaneous vasculitis occurs; may be restarted with a dose reduction once symptoms resolve and the ANC has decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: White blood cell counts of &ge;100,000/mm<sup>3</sup> have been reported with filgrastim doses &gt;5 mcg/kg/day. When filgrastim products are used as an adjunct to myelosuppressive chemotherapy, discontinue when absolute neutrophil count (ANC) exceeds 10,000/mm<sup>3</sup> after the ANC nadir has occurred (to avoid potential excessive leukocytosis). Doses that increase the ANC beyond 10,000/mm<sup>3</sup> may not result in additional clinical benefit. Monitor complete blood cell count (CBC) twice weekly during therapy. In patients receiving myelosuppressive chemotherapy, filgrastim discontinuation generally resulted in a 50% decrease in circulating neutrophils within 1 to 2 days, and a return to pretreatment levels in 1 to 7 days. When used for peripheral blood progenitor cell collection, discontinue filgrastim products if leukocytes &gt;100,000/mm<sup>3</sup>. Thrombocytopenia has also been reported with filgrastim products; monitor platelet counts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxicity: Based on findings of azotemia, hematuria (micro- and macroscopic), proteinuria, and renal biopsy, glomerulonephritis has occurred in patients receiving filgrastim. Glomerulonephritis usually resolved after filgrastim dose reduction or discontinuation. If glomerulonephritis is suspected, evaluate for cause; if likely due to filgrastim, consider dose reduction or treatment interruption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory distress syndrome: Acute respiratory distress syndrome (ARDS) has been reported. Evaluate patients who develop fever and lung infiltrates or respiratory distress for ARDS; discontinue in patients with ARDS.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Splenic rupture: Rare cases of splenic rupture have been reported (may be fatal); in patients with upper abdominal pain, left upper quadrant pain, or shoulder tip pain, withhold treatment and evaluate for enlarged spleen or splenic rupture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Severe chronic neutropenia: Establish diagnosis of severe chronic neutropenia (SCN) prior to initiation; use prior to appropriate diagnosis of SCN may impair or delay proper evaluation and treatment for neutropenia due to conditions other than SCN. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported to occur in the natural history of congenital neutropenia (without cytokine therapy). Cytogenetic abnormalities and transformation to MDS and AML have been observed with filgrastim when used to manage SCN, although the risk for MDS and AML appears to be in patients with congenital neutropenia. Abnormal cytogenetics and MDS are associated with the development of AML. The effects of continuing filgrastim products in patients who have developed abnormal cytogenetics or MDS are unknown; consider risk versus benefits of continuing treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Sickle cell disorders: May precipitate severe sickle cell crises, sometimes resulting in fatalities, in patients with sickle cell disorders (sickle cell trait or sickle cell disease); carefully evaluate potential risks and benefits. Discontinue in patients undergoing sickle cell crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytotoxic chemotherapy: Do not use filgrastim products in the period 24 hours before to 24 hours after administration of cytotoxic chemotherapy because of the potential sensitivity of rapidly dividing myeloid cells to cytotoxic chemotherapy. Transient increase in neutrophil count is seen 1 to 2 days after filgrastim initiation; however, for sustained neutrophil response, continue until post-nadir ANC reaches 10,000/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly patients: The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update recommend that prophylactic colony-stimulating factors be used in patients &ge;65 years with diffuse aggressive lymphoma treated with curative chemotherapy (eg, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), especially if patients have comorbid conditions (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric patients: Colony-stimulating factor (CSF) use in pediatric patients is typically directed by clinical pediatric protocols. The American Society of Clinical Oncology (ASCO) Recommendations for the Use of WBC Growth Factors Clinical Practice Guideline Update states that CSFs may be reasonable as primary prophylaxis in pediatric patients when chemotherapy regimens with a high likelihood of febrile neutropenia are employed. Likewise, secondary CSF prophylaxis should be limited to high-risk patients. In pediatric cancers in which dose-intense chemotherapy (with a survival benefit) is used, CSFs should be given to facilitate chemotherapy administration. CSFs should not be used in the pediatric population for non-relapsed acute lymphoblastic or myeloid leukemia when no infection is present (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiation therapy recipients: Avoid concurrent radiation therapy with filgrastim products; safety and efficacy have not been established with patients receiving radiation therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging of some dosage forms may contain latex. Granix (tbo-filgrastim), including all components, is not made with natural rubber latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Other warnings/precautions:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Filgrastim products should not be routinely used in the treatment of established neutropenic fever. CSFs may be considered in cancer patients with febrile neutropenia who are at high risk for infection-associated complications or who have prognostic factors indicative of a poor clinical outcome (eg, prolonged and severe neutropenia, age &gt;65 years, hypotension, pneumonia, sepsis syndrome, presence of invasive fungal infection, uncontrolled primary disease, hospitalization at the time of fever development) (Freifeld 2011; Smith 2006). CSFs should not be routinely used for patients with neutropenia who are afebrile. Dose-dense regimens that require CSFs should only be used within the context of a clinical trial or if supported by convincing evidence (Smith 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; International issues: Some products available internationally may have vial strength and dosing expressed as units (instead of as micrograms). Refer to prescribing information for specific strength and dosing information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nuclear imaging: Increased bone marrow hematopoietic activity due to colony-stimulating factor use has been associated with transient bone-imaging changes; interpret results accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor growth effects: The G-CSF receptor through which filgrastim products act has been found on tumor cell lines. May potentially act as a growth factor for any tumor type (including myeloid malignancies and myelodysplasia). When used for stem cell mobilization, may release tumor cells from marrow, which could be collected in leukapheresis product; potential effect of tumor cell reinfusion is unknown.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299335\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220395\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13301&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belotecan: Granulocyte Colony-Stimulating Factors may enhance the neutropenic effect of Belotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bleomycin: Filgrastim may enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Filgrastim may enhance the adverse/toxic effect of Cyclophosphamide. Specifically, the risk of pulmonary toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: Granulocyte Colony-Stimulating Factors may enhance the adverse/toxic effect of Tisagenlecleucel. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Granulocyte Colony-Stimulating Factors may enhance the myelosuppressive effect of Topotecan. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171175\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2734401\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Filgrastim has been shown to cross the placenta in humans. Information related to the use of granulocyte-colony stimulating factor (G-CSF) in pregnant patients with congenital, cyclic, or idiopathic neutropenia (Boxer 2015; Zeidler 2014) and G-CSF-induced allogeneic peripheral blood stem cells donation is limited (Leitner 2001; Shibata 2003). One review suggests avoiding use during the first trimester until additional outcome information is available (Pessach 2013). Data collected from the Severe Chronic Neutropenia International Registry (SCNIR) note dosing for chronic conditions may need adjusted in pregnant women; the lowest effective dose to maintain the absolute neutrophil count is recommended (Zeidler 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047357\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chemotherapy-induced neutropenia: Complete blood cell count (CBC) with differential and platelets prior to chemotherapy and twice weekly during growth factor treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bone marrow transplantation: CBC with differential and platelets frequently</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematopoietic radiation injury syndrome (acute): CBC at baseline (do not delay filgrastim for baseline CBC) and approximately every 3 days until ANC remains &gt;1,000/mm<sup>3</sup> for 3 consecutive CBCs. Estimate absorbed radiation dose (radiation exposure) based on information from public health authorities, biodosimetry (if available), or clinical findings (eg, onset of vomiting or lymphocyte depletion kinetics).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peripheral progenitor cell collection: Neutrophil counts after 4 days of filgrastim treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe chronic neutropenia: CBC with differential and platelets twice weekly during the first month of therapy and for 2 weeks following dose adjustments; once clinically stable, monthly for 1 year and quarterly thereafter. Monitor bone marrow and karyotype prior to treatment; and monitor marrow and cytogenetics annually throughout treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047361\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Blood samples for monitoring the hematologic effects of G-CSF should be drawn just before the next dose </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171167\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Filgrastim, filgrastim-sndz, and tbo-filgrastim are granulocyte colony stimulating factors (G-CSF) produced by recombinant DNA technology. G-CSFs stimulate the production, maturation, and activation of neutrophils to increase both their migration and cytotoxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171185\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Filgrastim: 1 to 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tbo-filgrastim: Time to maximum ANC: 3 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Filgrastim: Neutrophil counts generally return to baseline within 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tbo-filgrastim: ANC returned to baseline by 21 days after completion of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 150 mL/kg; Continuous infusion: No evidence of drug accumulation over a 11- to 20-day period</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Systemically degraded </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Filgrastim: SubQ: 60% to 70%; Tbo-filgrastim: SubQ: 33%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 4.4 &plusmn; 0.4 hours (Gillan 1994)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Filgrastim: ~3.5 hours; Tbo-filgrastim: 3 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: Filgrastim: 2 to 8 hours; Tbo-filgrastim: 4 to 6 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171189\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Neupogen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/mL (1 mL): $377.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/1.6 mL (1.6 mL): $601.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Granix Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.5 mL (0.5 mL): $359.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/0.8 mL (0.8 mL): $572.52</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Neupogen Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.5 mL (0.5 mL): $400.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/0.8 mL (0.8 mL): $637.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Zarxio Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.5 mL (0.5 mL): $330.79</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">480 mcg/0.8 mL (0.8 mL): $526.78</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171191\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Accofil (IE);</li>\n      <li>Ambigrast (PH);</li>\n      <li>Biocilin (MX);</li>\n      <li>Biofigran (CO);</li>\n      <li>Biofilgran (MX);</li>\n      <li>Endufil (PH);</li>\n      <li>Filatil (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Filgen (EC, LK, TH);</li>\n      <li>Filgrast (BD);</li>\n      <li>Gran (CN, JP, MY, PH, SG, TH, VN);</li>\n      <li>Granulokine (BR);</li>\n      <li>Grasin (KR);</li>\n      <li>Grastim (BD, LK);</li>\n      <li>Grastofil (IE);</li>\n      <li>Grimatin (JP);</li>\n      <li>Inmunef (MX);</li>\n      <li>Jiexin (CN);</li>\n      <li>Leuco-Plus (TH);</li>\n      <li>Leucogen (ID);</li>\n      <li>Leucostim (JO, KR);</li>\n      <li>Leukokine (ID);</li>\n      <li>Macroleuco (PH);</li>\n      <li>Neograstim (LB);</li>\n      <li>Neufil (BD);</li>\n      <li>Neukine (ID, TH);</li>\n      <li>Neulastim (AE, KW, SA);</li>\n      <li>Neupogen (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CL, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, NZ, OM, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Neutromax (PE, PY, VN);</li>\n      <li>Nivestim (AU, GB, HK, IE, MT, MY, TR);</li>\n      <li>Ratiograstim (GB);</li>\n      <li>Recombicyte (PH);</li>\n      <li>Religrast (LK, PH);</li>\n      <li>SciLocyte (PH);</li>\n      <li>Teva Grastim (AU);</li>\n      <li>Tevagastrim (IL);</li>\n      <li>Tevagrastim (HK);</li>\n      <li>White-C (PH);</li>\n      <li>Zarsio (UA);</li>\n      <li>Zarzio (GB, HK, HR, IE, MY, RO, SG, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. <i>N Engl J Med</i>. 1989;320(24):1574-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/2471075/pubmed\" target=\"_blank\" id=\"2471075\">2471075</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boxer LA, Bolyard AA, Kelley ML, et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. <i>Obstet Gynecol</i>. 2015;125(1):197-203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/25560125/pubmed\" target=\"_blank\" id=\"25560125\">25560125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boztug K, Welte K, Zeidler C, Klein C. Congenital neutropenia syndromes. <i>Immunol Allergy Clin North Am</i>. 2008;28(2):259-275.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/18424332/pubmed\" target=\"_blank\" id=\"18424332\">18424332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calhoun DA, Maheshwari A, Christensen RD. Recombinant granulocyte colony-stimulating factor administered enterally to neonates is not absorbed. <i>Pediatrics</i>. 2003;112(2):421-423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/12897302/pubmed\" target=\"_blank\" id=\"12897302\">12897302</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carr R, Brocklehurst P, Dor&eacute; CJ, et al. Granulocyte-Macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age heonates (the PROGRAMS trial): A single-blind, multicentre, randomised controlled trial.<i> Lancet</i>. 2009;373(9659):226-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/19150703/pubmed\" target=\"_blank\" id=\"19150703\">19150703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carr R, Modi N, Dor&eacute; C. G-CSF and GM-CSF for treating or preventing neonatal infections. <i>Cochrane Database Syst Rev</i>. 2003;3:CD003066.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/12917944/pubmed\" target=\"_blank\" id=\"12917944\">12917944</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    D&iacute;az MA, Kanold J, Vicent MG, Halle P, Madero L, Dem&eacute;ocq F. Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: a state-of-the-art review. <i>Bone Marrow Transplant</i>. 2000;26(12):1291-1298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/11223968/pubmed\" target=\"_blank\" id=\"11223968\">11223968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freifeld AG, Bow EJ, Sepkowitz KA, et al, &quot;Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients With Cancer: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2011;52(4):427-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/21205990/pubmed\" target=\"_blank\" id=\"21205990\">21205990</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gillan ER, Christensen RD, Suen Y, Ellis R, van de Ven C, Cairo MS. A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. <i>Blood</i>. 1994;84(5):1427-1433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/7520770 /pubmed\" target=\"_blank\" id=\"7520770 \">7520770 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gilmore MM, Stroncek DF, Korones DN. Treatment of alloimmune neonatal neutropenia with granulocyte colony-stimulating factor. <i>J Pediatr</i>. 1994;125(6 Pt 1):948-951.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/7527850 /pubmed\" target=\"_blank\" id=\"7527850 \">7527850 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Granix injection (tbo-filgrastim) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grastofil injection (filgrastim) [prescribing information]. Toronto, Ontario: Apotex Inc.; April 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <i>Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection</i>. Pediatric Adverse Drug Events. February 28, 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    H&ouml;glund M.Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference? <i>Med Oncol</i>. 1998;15(4):229-233.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/9951685 /pubmed\" target=\"_blank\" id=\"9951685 \">9951685 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hollingshead LM, Goa KL. Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions. <i>Drugs</i>. 1991;42(2):300-330.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/1717226/pubmed\" target=\"_blank\" id=\"1717226\">1717226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson PA, West NJ, Spadoni V, et al. Sterility of filgrastim (G-CSF) in syringes. <i>Ann Pharmacother</i>. 1996;30(11):1238-1242.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/913403/pubmed\" target=\"_blank\" id=\"913403\">913403</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leitner G, Loidolt H, Greinix HT, et al. Granulocyte colony-stimulating factor-induced allogeneic peripheral stem cell donation during early pregnancy.<i> Br J Haematol</i>. 2001;115(1):233-234.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/11722442/pubmed\" target=\"_blank\" id=\"11722442\">11722442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morstyn G, Campbell L, Lieschke G, et al. Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy. <i>J Clin Oncol</i>. 1989;7(10):1554-1562.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/2789274 /pubmed\" target=\"_blank\" id=\"2789274 \">2789274 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mueller BU, Jacobsen F, Butler KM, Husson RN, Lewis LL, Pizzo PA. Combination treatment with azidothymidine and granulocyte colony-stimulating factor in children with human immunodeficiency virus infection. <i>J Pediatr</i>. 1992;121(5 Pt 1):797-802.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/1279153/pubmed\" target=\"_blank\" id=\"1279153\">1279153</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neupogen injection (filgrastim) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; June 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pessach I, Shimoni A, Nagler A. Granulocyte-colony stimulating factor for hematopoietic stem cell donation from healthy female donors during pregnancy and lactation: what do we know? <i>Hum Reprod Update</i>. 2013;19(3):259-267.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/23287427/pubmed\" target=\"_blank\" id=\"23287427\">23287427</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. <i>Eur J Pediatr</i>. 1998;157(12):955-966.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/9877032/pubmed\" target=\"_blank\" id=\"9877032\">9877032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shibata H, Yamane T, Aoyama Y, et al. Excretion of granulocyte colony-stimulating factor into human breast milk. <i>Acta Haematol</i>. 2003;110(4):200-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/14663166/pubmed\" target=\"_blank\" id=\"14663166\">14663166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singh RF, Corelli RL, and Guglielmo BJ. Sterility of unit dose syringes of filgrastim and sargramostim. <i>Am J Hosp Pharm</i>. 1994;51(15):2811-2812.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/7531941/pubmed\" target=\"_blank\" id=\"7531941\">7531941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>J Clin Oncol</i>. 2015;33(28):3199-3212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/26169616/pubmed\" target=\"_blank\" id=\"26169616\">26169616</a>]</span><span class=\"doi\">10.1200/JCO.2015.62.3488</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. <i>J Clin Oncol</i>. 2006;24(19):3187-3205.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/16682719/pubmed\" target=\"_blank\" id=\"16682719\">16682719</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology. <i>J Clin Oncol</i>. 1996;14(6):1957-1960.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/8656266/pubmed\" target=\"_blank\" id=\"8656266\">8656266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner LM, Furman WL. Haemopoietic growth factors in paediatric oncology: a review of the literature. <i>Paediatr Drugs</i>. 2001;3(3):195-217.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/11310717/pubmed\" target=\"_blank\" id=\"11310717\">11310717</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. <i>Semin Hematol</i>. 2006;43(3):189-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/16822461/pubmed\" target=\"_blank\" id=\"16822461\">16822461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolach B. Neonatal sepsis: pathogenesis and supportive therapy. <i>Semin Perinatol</i>. 1997;21(1):28-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/9190031/pubmed\" target=\"_blank\" id=\"9190031\">9190031</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zarxio injection (filgrastim-sndz) [prescribing information]. Princeton, NJ: Sandoz, Inc.; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeidler C, Grote UA, Nickel A, et al. Outcome and management of pregnancies in severe chronic neutropenia patients by the European Branch of the Severe Chronic Neutropenia International Registry.<i> Haematologica</i>. 2014;99(8):1395-1402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/filgrastim-including-biosimilars-of-filgrastim-pediatric-drug-information/abstract-text/24997149/pubmed\" target=\"_blank\" id=\"24997149\">24997149</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13301 Version 150.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F171203\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F171204\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047358\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11442533\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047351\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F171179\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F171164\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F22627092\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047363\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F171199\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047362\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F171257\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171253\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F171186\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171168\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299335\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220395\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F171175\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2734401\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047357\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1047361\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171167\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F171185\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F171189\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F171191\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13301|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-drug-information\" class=\"drug drug_general\">Filgrastim (including biosimilars of filgrastim): Drug information</a></li><li><a href=\"topic.htm?path=filgrastim-including-biosimilars-of-filgrastim-patient-drug-information\" class=\"drug drug_patient\">Filgrastim (including biosimilars of filgrastim): Patient drug information</a></li></ul></div></div>","javascript":null}